

---

# Drugs & Aging

## Supplement

---

### Reassessment of the Safety of Anti-Osteoarthritis Medications

**Guest Editor**

*Jean-Yves Reginster*

Department of Public Health,  
Epidemiology and Health Economics,  
University of Liège, Belgium

WHO Collaborating Centre for Public  
Health Aspects of Musculoskeletal Health and Aging,  
Liège, Belgium

Chair for Biomarkers of Chronic Diseases,  
Biochemistry Department,  
College of Science,  
King Saud University, Riyadh,  
Kingdom of Saudi Arabia

[jyreginster@uliege.be](mailto:jyreginster@uliege.be)

**Disclosures** This Supplement is published on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Working Group on the safety of anti-osteoarthritis medications: Nasser Al-Daghri, Nigel Arden, Bernard Avouac, Olivier Bruyère, Roland Chapurlat, Philip Conaghan, Cyrus Cooper, Elizabeth Curtis, Elaine Dennison, Nicholas Fuggle, Gabriel Herrero-Beaumont, Germain Honvo, Margreet Kloppenburg, Stefania Maggi, Tim McAlindon, Alberto Migliore, Ouafa Mkinsi, François Rannou, Jean-Yves Reginster, René Rizzoli, Roland Roth, Thierry Thomas, Daniel Uebelhart, and Nicola Veronese.

**Role of the Funding Source** The Working Group was entirely funded by the ESCEO, a Belgian not-for-profit organization. The ESCEO receives unrestricted educational grants, to support its educational and scientific activities, from Non-Governmental Organizations, not-for-profit organizations, non-commercial and corporate partners. The choice of topics, participants, content and agenda of the working groups as well as the writing, editing, submission and reviewing of the manuscript are under the sole responsibility of the ESCEO, without any influence from third parties.